INdians Followed for INtensive Lipid Lowering Treatment and Its safetY (INFINITY)

This study has been terminated.
(Poor enrollment)
Sponsor:
Collaborators:
Merck Frosst Canada Ltd.
Schering-Plough
Information provided by:
Sunnybrook Health Sciences Centre
ClinicalTrials.gov Identifier:
NCT00664469
First received: April 1, 2008
Last updated: July 27, 2011
Last verified: July 2011
  Purpose

In South Asian Canadians with documented coronary artery disease or diabetes and hypercholesterolemia with LDL-C levels > 2.0 mmol/L after 4 weeks of monotherapy with any statin: To compare the percent (%) of patients who achieve an LDL-C concentration of 2.0mmol/L after a 6-week course of treatment with ezetimibe 10 mg/day co-administered with any statin at any dose versus doubling of the current statin dose.


Condition Intervention Phase
Hypercholesterolemia
Drug: ezetimibe
Drug: Comparator: Simvastatin 20, 40 and 80 mg
Drug: Comparator: Atorvastatin
Drug: Comparator: Rosuvastatin
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: INdians Followed for INtensive Lipid Lowering Treatment and Its safetY: To Assess The Safety And Effectiveness Of Ezetimibe Co-Administered With Any Statin Compared To Doubling Of Current Statin Daily Dose In South Asian Canadians

Resource links provided by NLM:


Further study details as provided by Sunnybrook Health Sciences Centre:

Primary Outcome Measures:
  • The primary measure of efficacy will be the percentage of patients in each treatment arm achieving a target LDL-C > 2.0 mmol/L at week 6 assessment. This will be calculated as the percentage of patients achieving this end point at 6 weeks of treatment us [ Time Frame: 6 weeks of treatment ] [ Designated as safety issue: No ]

Enrollment: 64
Study Start Date: August 2007
Study Completion Date: November 2010
Primary Completion Date: March 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: EZE+statin
ezetimibe 10 mg per day is added to actual statin regimen for 6 weeks followed by another 6 weeks if at goal or statin dose can be doubled.
Drug: ezetimibe
ezetimibe 10 mg/day over a 6-week course of treatment.
Active Comparator: Stat2
patients on statins has their dose doubled for 6 weeks followed by another 6 weeks in which ezetimibe is added or the statin dose is doubled again.
Drug: Comparator: Simvastatin 20, 40 and 80 mg
Simvastatin 20, 40 and 80 mg; actual statin regimen for 6 weeks followed by another 6 weeks if at goal or statin dose can be doubled.
Drug: Comparator: Atorvastatin
Atorvastatin 20, 40 & 80 mg; actual statin regimen for 6 weeks followed by another 6 weeks if at goal or statin dose can be doubled.
Drug: Comparator: Rosuvastatin
Rosuvastatin 10, 20 & 40 mg; actual statin regimen for 6 weeks followed by another 6 weeks if at goal or statin dose can be doubled.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • According To The Judgment Of The Treating Physician, Changing Of The Current Regimen Or Doubling Of The Current Statin Dose Would Be Indicated For The Management Of The Patients Hypercholesterolemia
  • All Women Of Childbearing Potential Must Be Practicing An Effective Method Of Contraception Beginning At Least Seven (7) Days Prior To The Study And Continuing At Least 14 Days After Study Completion Or After Study Discontinuation All Women Of Childbearing Potential Must Be Practicing An Effective Method Of Contraception Beginning At Least Seven (7) Days Prior To The Study And Continuing At Least 14 Days After Study Completion Or After Study Discontinuation
  • Patient Is Male Or Female >= 18 Years Of Age
  • Patient Is Of South Asian Descent, Specifically Canadian Citizens Or Landed Immigrants With Ethnic Background From India, Pakistan, Nepal, Bangladesh Or Sri Lanka.
  • Patients With A Diagnosis Of Primary Hypercholesterolemia And Who Are Defined As Being "High Risk" With A Diagnosis Of Cad Or Diabetes, Either By Past Medical History Or By Angiographic Or Laboratory Evidence
  • The Patient Has Serum Ldl-C > 2.0 Mmol/L While On Any Statin At Below Maximum (10 Mg, 20 Mg Or 40 Mg/Day) Daily Dose For A Minimum Of Four Weeks Prior To The Baseline Visit

Exclusion Criteria:

  • Any Condition Which, In The Opinion Of The Investigator, Would Be Likely To Render The Patient Unable To Complete The Study Or For Which Study Participation Would Produce Significant Risk Or Not Be In The Best Interests Of The Patient
  • Cancer Within The Past 5 Years (Except For Successfully Treated Basal And Squamous Cell Carcinoma)
  • Disorders Of The Hematologic, Digestive (Including Malabsorptive Disorders), Or Central Nervous System Including Cerebrovascular Disease And Degenerative Diseases That Would Limit Study Evaluation Or Participation
  • Doubling Of The Current Statin Dose Is Not Possible Due To Tolerability Or Safety Concerns Or Because The Patient Is Already On The Maximum Statin Dose (C.F. Individual Statin Monograph)
  • Female Patient Receiving Hormone Therapy Not On A Stable Dose And Regimen For At Least 8 Weeks Prior To Visit 1 Or Is Unwilling To Continue The Same Regimen Throughout The Study
  • History Of Mental Instability, Drug/Alcohol Abuse Within The Past 5 Years, Or Major Psychiatric Illness Not Adequately Controlled And Stable On Pharmacotherapy
  • Individuals With Poor Mental Function, Drug Or Substance Abuse, Or Individuals With Unstable Psychiatric Illnesses, Which, In The Opinion Of The Investigator, May Interfere With Optimal Participation In The Study. Alcoholic Substance Abuse Would Be Defined As A Patient With Alcohol Consumption > 14 Drink Per Week. (A Drink Is: A Can Of Beer, Glass Of Wine, Or Single Measure Of Spirits)
  • Medications That Are Potent Inhibitors Of Cyp3a4, Including Cyclosporin, Systemic Itraconazole Or Ketoconazole, Erythromycin, Telithromycin Or Clarithromycin, Nefazodone, Protease Inhibitors. In Addition, Patients Should Not Take Amiodarone, Verapamil, Or Danazol. Patient Is Consuming > 950ml (> 1 Quart) Of Grapefruit Juice/Day
  • Non-Statin Lipid-Lowering Agents Including Fish Oils, Cholestin, Bile Acid Sequestrants, And Niacin (>200 Mg/Day) Taken Within 6 Weeks And Fibrates Within 8 Weeks Prior To Randomization At Visit 2 (Day 1)
  • Oral Corticosteroids (Unless Used As Replacement Therapy For Pituitary/Adrenal Disease And On A Stable Regimen For At Least 6 Weeks Prior To Visit 1).
  • Patient Has Liver Transaminases (Alt, Ast) > 50% Above The Upper Limit Of Normal At Screening (Visit 1) Or Active Liver Disease, And/Or Creatine Kinase (Ck) >50% Above The Upper Limit Of Normal (ULN)
  • Patient Who Is Known Hiv Positive
  • Patients Taking A Statin Medication Requiring Or Likely To Require Treatment With Prohibited Agents: Those With Known Interactions With Statins Including Antifungal Azoles (Itraconazole And Ketoconazole), Macrolide Antibiotics (Erythromycin And Clarithromycin), Nefazodone And Protease Inhibitors, Amiodarone And Verapamil
  • Patients That Are Treatment Naive For Statins
  • Patients Who Have Been Treated With Any Other Investigational Drug Within 30 Days Prior To Visit 1. (If < 30 Days, Contact The Clinical Monitor For A Case-By-Case Evaluation.)
  • Serum Creatinine >2.0 Mg/Dl Or 177 Micromol/L At Screening Visit (Visit 1), Or Active Renal Disease With Significant Proteinuria (>1 Mg Albumin/Mg Creatinine), Or Nephrotic Syndrome At Visit 1
  • Uncontrolled Endocrine Or Metabolic Disease Known To Influence Serum Lipids Or Lipoproteins (I.E. Secondary Causes Of Hyperlipidemia) Or Secondary Hypercholesterolemia Due To Hypothyroidism [T4 < 51.48nmol/L (< 4 Microg/Dl)] At Visit 1
  • Use Of Therapeutic Doses Of Corticosteroids For Conditions Which, In The Opinion Of The Investigator, Are Likely To Require The Use Of Therapeutic Corticosteroid Therapy During The Subjects Period Of Participation In The Study
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00664469

Locations
Canada, Quebec
Merck Frosst Canada Ltd.
Kirkland, Quebec, Canada, H9H 3L1
Sponsors and Collaborators
Sunnybrook Health Sciences Centre
Merck Frosst Canada Ltd.
Schering-Plough
Investigators
Study Director: Medical Monitor Merck Sharp & Dohme Corp.
  More Information

Additional Information:
No publications provided

Responsible Party: Dr Mina Madan/Cardiologist, Schulich Heart Centre, Sunnybrook Health Sciences Centre
ClinicalTrials.gov Identifier: NCT00664469     History of Changes
Other Study ID Numbers: 2008_006, MK0653-153
Study First Received: April 1, 2008
Last Updated: July 27, 2011
Health Authority: Canada: Health Canada

Additional relevant MeSH terms:
Hypercholesterolemia
Hyperlipidemias
Dyslipidemias
Lipid Metabolism Disorders
Metabolic Diseases
Simvastatin
Atorvastatin
Rosuvastatin
Ezetimibe
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Hypolipidemic Agents
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Lipid Regulating Agents
Therapeutic Uses
Anticholesteremic Agents
Enzyme Inhibitors

ClinicalTrials.gov processed this record on July 20, 2014